Genmab reported DKK9.07B in Cash and Equivalent for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Agios Pharmaceuticals AGIO:US $ 88.54M 8.52M
Amarin AMRN:US $ 228M 8.85M
Amgen AMGN:US $ 7183M 655M
Artemis Alpha ATS:LN 7.15M 672K
AstraZeneca AZN:LN 4817M 945M
Bayer BAYN:GR € 5785M 1221M
Biomarin Pharmaceutical BMRN:US $ 619.8M 14.36M
Bluebird Bio BLUE:US $ 173.15M 66.89M
Exelixis EXEL:US $ 723.27M 76.1M
Fresenius Medical Care FME:GR € 1025M 148.34M
Genmab GEN:DC DK 9071M 114M
GlaxoSmithKline GSK:LN 6465M 4502M
GN Store Nord GN:DC DK 959M 5249M
Hikma Pharmaceutical HIK:LN 23M 1000K
Immunogen IMGN:US $ 373.87M 63.79M
Insmed INSM:US $ 416.08M 99.63M
Lonza Group LONN:SW 1.53B 56M
Novartis NOVN:VX SF 3625M 10227M
Regeneron Pharmaceuticals REGN:US $ 3395.1M 49.4M
Seattle Genetics SGEN:US $ 364.87M 103.88M